Synplogen and ARCALIS Entered into a Business Alliance Agreement to Promote the Development and Manufacturing of mRNA Therapeutics and Vaccines
Synplogen Co., Ltd. (Head Office: Chuo-ku, Kobe; hereinafter referred to as “Synplogen”) and ARCALIS, Inc. (Head Office: Minamisoma, Fukushima; hereinafter referred to as “ARCALIS”) have concluded a business alliance agreement to advance the development and manufacturing of mRNA therapeutics and vaccines by maximizing each other’s technologies, knowledge, and resources.
Synplogen has proprietary technologies in mRNA sequence design, plasmid DNA synthesis, and template DNA synthesis and manufacturing. ARCALIS provides services related to mRNA coding region (CDS) sequence design and drug substance manufacturing, LNP bulk manufacturing, LNP bulk formulation, filling and finishing. By collaborating to establish an integrated end-to-end service system from development to manufacturing, the two companies aim to deliver high-quality mRNA therapeutics and vaccines quickly to customers.
“By working closely with ARCALIS, a leading development partner capable of GMP-compliant manufacturing, we look forward to further strengthening our development and manufacturing value chain to accelerate the practical application of mRNA therapeutics.” (Kazuhiko Yamamoto, Representative Director, CEO, Synplogen)
“We are very pleased to have entered into this business partnership agreement with Synplogen. Through this collaboration, we aim to contribute to a healthier future for people around the world by providing a seamless, end-to-end service for the development and manufacture of high-quality, reliable mRNA therapeutics and vaccines to a diverse range of customers, including academia, startups, and pharmaceutical companies, both domestically and internationally.” (Satoshi Takamatsu, Representative Director, President and CEO, ARCALIS)
About Synplogen: https://www.synplogen.com/en/
Synplogen is a synthetic biology startup spun out from Kobe University, and it is developing services for long and complex DNA synthesis and DNA library construction with a variety of combinations, using its unique DNA synthesis technology, OGAB™ method, and its DNA library construction technology, Combinatorial-OGAB™ (Combi-OGAB™) method. In addition, as a bio-foundry specializing in the field of gene therapy, we provide high-quality, cost-effective “Gene Therapy Biofoundry™” services. Specifically, we provide one-stop solution services at our own R&D center in Kobe, from DNA synthesis and large-scale preparation of plasmid DNA to the design and development of viral vectors and mRNA, development of manufacturing processes, characterization and quality testing, and technology transfer to development partner companies that own GMP-compliant manufacturing facilities.
About ARCALIS: https://corp.arcalis.co.jp/en/
ARCALIS is an mRNA vaccines and therapeutics contract development and manufacturing organization (CDMO), jointly established by Axcelead, Inc. (Representative Director, President and CEO: Nobuhiro Todokoro) and Arcturus Therapeutics, Inc. (NASDAQ: ARCT). ARCALIS aims to develop the world’s first mRNA vaccines and therapeutics CDMO business that promises a stable supply of high-quality mRNA therapeutics to all customers, including Arcturus, other pharmaceutical companies, biotech companies, and academia institutes worldwide. The new facility in the city of Minamisoma, Fukushima Prefecture, is equipped with state-of-the-art manufacturing and quality control systems that meet the cGMP standards for pharmaceuticals.